Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1321 to 1335 of 2185 results for guidelines

  1. What symptoms do children, young people, pregnant women and older people with suspected post‑COVID‑19 syndrome present with?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  2. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA902

  3. What is the clinical effectiveness of D-dimer and other blood tests and clinical features as prognostic markers of developing post‑COVID‑19 syndrome?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  4. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  5. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

    Medtech innovation briefing
    Published
    15 December 2020

  6. EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)

    NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration

    Medtech innovation briefing
    Published
    22 January 2016

  7. Radiation-induced lymphopenia and risk of new COVID-19 and severity of COVID-19: Does radiation-induced lymphopenia predispose patients to an increased risk of new COVID-19 and does it contribute to patients developing more severe COVID-19?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  8. What interventions are effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK?

    or planning a return to work are treated consistently.The focus of this guideline is on managing sickness absence among all employees,...

    Research recommendation
    Published
    10 February 2020

  9. Duration of risk of radiotherapy in people with cancer and COVID-19: Are people who have had radiotherapy recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had radiotherapy less recently?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of radiotherapy Number NG162 Date issued

    Research recommendation
    Published
    21 October 2021

  10. What is the prevalence and incidence of post-COVID-19 syndrome in patients who have received single, double, or boosted doses of the approved vaccinations in the UK? Does this vary across different population groups (for example in black, Asian and minority ethnic group communities)?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    12 November 2021

  11. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

    Evidence summary
    Published
    24 February 2021

  12. 3C Patch for treating diabetic foot ulcers (HTG615)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

    HealthTech guidance
    Published
    7 March 2022
    View recommendations

    Sections for HTG615

  13. MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

    HealthTech guidance
    Last updated
    5 July 2022
    View recommendations

    Sections for HTG275

  14. Prostate-specific antigen testing: What is the diagnostic accuracy of using age-adjusted and fixed prostate-specific antigen thresholds for people with symptoms of prostate cancer, including those at high risk of developing prostate cancer (such as those with an African family background or a family history of prostate cancer)?

    population that had already been referred to secondary care. The 2019 guideline recommended referral if PSA levels were above the...

    Research recommendation
    Published
    7 January 2022

  15. Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had SACT less recently?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of systemic anticancer treatments Number NG161

    Research recommendation
    Published
    21 October 2021